AZD0292

Pipeline

Status by Indication[3][1]

Competition

Competitive Landscape

76 competitors in Bronchiectasis

#DrugCompanyPhaseTrials

1

Theo-Dur

Pfizer

Approved

22

Garamycin

SSchering-Plough

Approved

13

Symbicort

AstraZeneca

Approved

14

Alkeran

AApotex Inc.

Approved

—5

Aztreonam Lysine

Gilead

Approved

16

Osmitrol

BB. Braun Medical Inc.

Phase 3

17

Deltavit

HHyundai Pharmaceutical Co., LTD.

Phase 3

18

Spiriva

Boehringer Ingelheim

Approved

19

Daliresp

AstraZeneca

Phase 2

410

Colomycin

UUniversity of Edinburgh

Approved

1Show 25 more competitors

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Clinical

Trials by Indication[1]

Single Ascending Dose1 trial

A Study to Assess the Safety, Tolerability, and Pharmacokinetics of a Single Ascending Dose of AZD0292 In Healthy Participants

Completed·AstraZeneca·Phase 1·NCT06311760·32 enrolled

Pseudomonas Aeruginosa1 trial

A Phase IIb Randomized, Double-blind, Placebo-controlled, Parallel, Multidose Study to Evaluate the Efficacy, Safety, and PK of AZD0292 in Participants 12 Years of Age and Older With Bronchiectasis and Chronic Pseudomonas Aeruginosa Colonization

Recruiting·AstraZeneca·Phase 2·NCT07088926·435 enrolled

Unspecified1 trial

A Phase I, Randomized, Double-blind, Placebo-controlled Study to Assess the Safety, Tolerability, and Pharmacokinetics of AZD0292 Following Single Ascending Dose Administration to Healthy Japanese Participants

Active, not recruiting·AstraZeneca·Phase 1·NCT07222254·18 enrolled

Details

Drug Info

Related News